Next Steps in Cell Therapy
Paul Lammers, MD, MSc, talks about the future of cell therapies and the applications of TAC-01 in solid tumors.
In the third of 3 videos, Paul Lammers, MD, MSc, chief executive officer of Triumvira, talks about the company’s unique T antigen coupler (TAC) T-cell technology and the future of TAC-01 in solid tumors. Daniel Olson, MD, assistant professor of medicine, the University of Chicago Medicine, presented an abstract about the phase 1/2 trial evaluating TAC-01 in HER2-expressing tumors at the Society for Immunotherapy of Cancer 38th Annual Meeting held November 1-5, 2023.
Related: Advancements in Cell Therapy for Solid Tumors
About the Phase 1/2 Trial of TAC-01 in HER2-Expressing Solid Tumors
Transcription:
0:09 | The challenge with cells, in general, with cell therapy, it's relatively easy, relative, in liquid tumors, because the tumor cells are either in your lymph system or in your vascular system, right? It's easy to get through. For solid tumors, it's tough because the cells need to extravasate out of the blood streams, through the stroma, find the tumor and get through the basal membrane get into the tumor cells. I mean, it's a long process for the cells to get there, which is a challenge. I'm interested to see what's going to happen in pancreatic, because as we all know, pancreatic cancer is one of the toughest cancer types. Why? It has very high interest into tumor pressure, it's very difficult to get anything into a pancreatic cancer. So we hope to see if we can get the cells to penetrate there. The other thing is the brain, right?
0:58 | Of course, they are pursuing glioblastoma, neuroblastoma cell therapies. I do think we all know that, that if a patient has brain cancer and the blood brain barrier is changes is more leaky, which means the cells can get in there. But the question is, do you give it into the tumor? Into a ventricle? Do you give it into the spinal fluid? Do you give it still IV? So a lot there is still to be figured out in the coming years. But whether it's, you know, lung, endometrial, ovarian, I mean, there's so many opportunities with cell therapy, because at the end of the day, these are still the most powerful drugs. What is up with these TAC T cells? There's something special about these cells.
